Abstract:Mutation of the isocitrate dehydrogenase (IDH) gene is regarded a novel indicator for the prognosis of patients with glioma. However, the role of the IDH1 gene mutations in carcinogenesis and the mechanisms underlying their function in glioblastoma multiforme (GBM) remain unknown. The present study aimed to determine whether the association of RLIP76 with the different IDH1 mutational status could serve as a puta‐ tive biomarker for improving disease prognosis. Quantitative PCR, western blotting and immunohistochemical staining assays were used to investigate the expression levels of RLIP76 in 124 patients with GBM with different IDH1 mutational status. In addition, the association between RLIP76 expression, IDH1 mutational status and clinicopathological characteristics was investigated. The effects of RLIP76 expression and IDH1 mutational status on cell proliferation, cell apoptosis, and cell signaling were examined by Cell Counting Kit‐8, flow cytometry and western blot assays, respectively. The data demonstrated that IDH1 wild‐type (IDH1Wt) patients with low RLIP76 expression exhibited improved overall and progression‐free survival. This effect was not observed in patients with IDH1 mutant (IDH1Mut) GBM. In vitro assays demonstrated that knockdown of IDH1 or overexpression of the IDH1 R132H mutation suppressed cell proliferation and promoted cell apoptosis in U87 glioma cells. Mechanistic studies further indicated that although the IDH1 R132H mutant phenotype exhibited similar antitumor effects on GBM cells as those observed with the IDH1 knockdown, it acted via a different mechanism with regard to the regulation of the apoptosis signaling pathway. IDH1 R132H mutant cells promoted p53‐induced apoptosis, while the IDH1 knockdown inhibited the RLIP76‐dependent apoptotic pathway in glioma cells. The findings of the present study provided insight to the contribution of IDH1 mutation in the development of GBM and indicated that RLIP76 may be considered as a prognostic biomarker of IDH1Wt GBM.

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

Mutation of Isocitrate Dehydrogenase 1 Induces Glioma Cell Proliferation Via Nuclear Factor-Κb Activation in a Hypoxia-Inducible Factor 1-Α Dependent Manner.

IDH1/2 Mutations Target a Key Hallmark of Cancer by Deregulating Cellular Metabolism in Glioma

IDH1 Mutation Inhibits Differentiation of Astrocytes and Glioma Cells with Low Oxoglutarate Dehydrogenase Expression by Disturbing Α-Ketoglutarate-related Metabolism and Epigenetic Modification

IDH1-R132H Mutation Radiosensitizes U87MG Glioma Cells Via Epigenetic Downregulation of TIGAR.

IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma

IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced

IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.

R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.

IDH1 Arg-132 Mutant Promotes Tumor Formation Through Down-Regulating P53.

IDH gene mutation in glioma

IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation.

Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.

IDH1 mutation decreases the invasiveness of glioma by downregulating the expression and activity of TAZ

Idh1 Mutations Inhibit Multiple Alpha-Ketoglutarate-Dependent Dioxygenase Activities In Astroglioma

Overexpression of isocitrate dehydrogenase-1R¹³²H enhances the proliferation of A172 glioma cells via aerobic glycolysis.

Abstract. Mutation of the isocitrate dehydrogenase (IDH) gene is regarded a novel indicator for the prognosis of patients with glioma. However, the role of the IDH1 gene mutations in carcinogenesis and the mechanisms underlying their function in glioblastoma multiforme

Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma

IDH1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma

Lactate dehydrogenase A silencing in IDH mutant gliomas

IDH1 Mutation Impairs Antiviral Response and Potentiates Oncolytic Virotherapy in Glioma